24/7 Market News Snapshot 29 May, 2025 – Silexion Therapeutics Corp Ordinary Shares (NASDAQ:SLXN)

May 29, 2025

DENVER, Colo., 29 May, 2025 (www.247marketnews.com) – (NASDAQ:SLXN) are discussed in this article.
Silexion Therapeutics Corp (SLXN) has demonstrated notable market performance, with its stock price climbing to $1.064 during pre-market trading, reflecting a 10.37% increase from the previous close of $0.964. This upward momentum is complemented by significant trading volume of 7.39 million shares, indicating strong investor engagement and the potential for further price appreciation. Traders are advised to monitor technical indicators like RSI and MACD to assess market conditions, particularly as the stock approaches key resistance levels around $1.07.

Concurrently, Silexion has unveiled promising preclinical results for its pioneering RNA interference (RNAi) therapy, SIL204, aimed at treating KRAS-driven cancers. Recent studies reveal that SIL204 showcases substantial efficacy against a variety of human cancer cell lines, including those linked to pancreatic, colorectal, and lung cancers, thereby addressing critical unmet medical needs in oncology. The data indicates that SIL204 significantly inhibits cell proliferation and metabolic activity within KRAS G12D mutation-bearing cancer cells, achieving up to 90% reduction in cell viability at nanomolar concentrations.

Ilan Hadar, Chairman and CEO of Silexion Therapeutics, emphasized the transformative potential of SIL204, suggesting that its versatile RNAi approach could offer new treatment avenues for various KRAS-driven malignancies beyond pancreatic cancer. The therapy utilizes an advanced lipid-conjugated delivery system to enhance RNA delivery into cells, positioning Silexion at the forefront of cancer treatment innovation.

Silexion plans to advance its research efforts, focusing next on lung cancer cell lines to further explore SIL204’s capabilities. Given the prevalence of KRAS mutations in aggressive cancers, which affect approximately 90% of pancreatic and 45% of colorectal cases, Silexion is poised to make significant contributions to cancer therapeutics, aiming for improved patient outcomes in challenging oncological landscapes.

Related news for (SLXN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.